Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

BACKGROUND: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild to moderate coronavirus disease 2019 (COVID-19) in patients at high risk for developing severe disease or hospitalization. Their safety and efficacy have not been specifically evaluated in solid org...

Descripción completa

Detalles Bibliográficos
Autores principales: Yetmar, Zachary A, Beam, Elena, O’Horo, John C, Ganesh, Ravindra, Bierle, Dennis M, Brumble, Lisa, Seville, Maria Teresa, Razonable, Raymund R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494079/
https://www.ncbi.nlm.nih.gov/pubmed/34631921
http://dx.doi.org/10.1093/ofid/ofab255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494079/
https://www.ncbi.nlm.nih.gov/pubmed/34631921
http://dx.doi.org/10.1093/ofid/ofab255

Ejemplares similares